Pre-HCT demographic and clinical characteristics of study population
| . | All patients (N = 1266) . | Day +100 cohort (n = 935) . |
|---|---|---|
| Median age at HCT (range), y | 57 (18-81) | 55 (18-77) |
| Female sex, n (%) | 588 (46) | 438 (47) |
| Disease, n (%) | ||
| All AML | 1115 (88) | 851 (91) |
| De novo AML | 870 (69) | 678 (73) |
| Secondary AML | 245 (19) | 173 (19) |
| MDS/AML | 151 (12) | 84 (9) |
| Cytogenetics at diagnosis, n (%) | ||
| Favorable | 75 (6) | 67 (7) |
| Intermediate | 810 (64) | 634 (68) |
| Adverse | 334 (26) | 201 (21) |
| Missing | 47 (4) | 33 (4) |
| Remission status at HCT, n (%) | ||
| First remission | 1009 (80) | 760 (81) |
| Second remission | 257 (20) | 175 (19) |
| Pre-HCT MRD by flow cytometry, n (%) | 261 (21) | 136 (15) |
| Cytogenetics before HCT, n (%) | ||
| Normalized karyotype | 472 (37) | 361 (39) |
| Abnormal karyotype | 236 (19) | 134 (14) |
| Noninformative data∗ | 558 (44) | 440 (47) |
| Recovered peripheral blood counts before HCT,† n (%) | 891 (70) | 677 (72) |
| HCT-CI score, n (%) | ||
| 0-1 | 483 (38) | 367 (39) |
| 2-3 | 425 (34) | 314 (34) |
| ≥4 | 344 (27) | 246 (26) |
| Missing | 14 (1) | 8 (1) |
| HLA matching, n (%) | ||
| 10/10 HLA-identical related donor | 288 (23) | 214 (23) |
| 10/10 HLA-matched unrelated donor | 633 (50) | 471 (50) |
| 1-2 allele/antigen-mismatched unrelated donor | 137 (11) | 99 (11) |
| HLA-haploidentical donor | 51 (4) | 37 (4) |
| Umbilical cord blood | 157 (12) | 114 (12) |
| Source of stem cells, n (%) | ||
| Peripheral blood | 1022 (81) | 762 (81) |
| Bone marrow | 87 (7) | 59 (6) |
| Umbilical cord blood | 157 (12) | 114 (12) |
| Conditioning intensity, n (%) | ||
| MAC | 734 (58) | 569 (61) |
| Non-MAC | 532 (42) | 366 (39) |
| GVHD prophylaxis, n (%) | ||
| CNI + MMF w/wo sirolimus | 609 (48) | 418 (45) |
| CNI + MTX w/wo other | 457 (36) | 365 (39) |
| PTCy | 184 (15) | 139 (15) |
| Other | 16 (1) | 13 (1) |
| Post-HCT MRD status day +20 to +40, n (%) | ||
| MRDneg | 1123 (89) | 902 (96) |
| MRDpos | 99 (8) | 15 (2) |
| Not assessed | 44 (3) | 18 (2) |
| Post-HCT MRD status day +70 to +100, n (%) | ||
| MRDneg | 983 (78) | 924 (99) |
| MRDpos | 131 (10) | 11 (1) |
| Not assessed | 152 (12) | 0 (0) |
| Pre-HCT/day +70 to +100 post-HCT MRD dynamics, n (%) | ||
| MRDneg/MRDneg | 839 (66) | 798 (85) |
| MRDneg/MRDpos | 60 (5) | 1 (<1) |
| MRDpos/MRDneg | 144 (11) | 126 (13) |
| MRDpos/MRDpos | 71 (6) | 10 (1) |
| Not assessed | 152 (12) | 0 (0) |
| Day +20-40/day +70 to +100 post-HCT MRD dynamics, n (%) | ||
| MRDneg/MRDneg | 945 (75) | 897 (96) |
| MRDneg/MRDpos | 82 (6) | 5 (1) |
| MRDpos/MRDneg | 19 (2) | 9 (1) |
| MRDpos/MRDpos | 48 (4) | 6 (1) |
| Not assessed | 172 (14) | 18 (2) |
| CD3 chimerism day +70 to +100, n (%) | ||
| Mixed (<95%) | 307 (24) | 240 (26) |
| Full (≥95%) | 565 (45) | 474 (51) |
| Not assessed | 394 (31) | 221 (24) |
| Decreasing CD3 chimerism day +20 to +40 to day +70 to +100, n (%) | ||
| No (increase or <20% decrease) | 689 (54) | 564 (60) |
| Yes (≥20 decrease) | 14 (1) | 8 (1) |
| Not assessed | 563 (44) | 363 (36) |
| . | All patients (N = 1266) . | Day +100 cohort (n = 935) . |
|---|---|---|
| Median age at HCT (range), y | 57 (18-81) | 55 (18-77) |
| Female sex, n (%) | 588 (46) | 438 (47) |
| Disease, n (%) | ||
| All AML | 1115 (88) | 851 (91) |
| De novo AML | 870 (69) | 678 (73) |
| Secondary AML | 245 (19) | 173 (19) |
| MDS/AML | 151 (12) | 84 (9) |
| Cytogenetics at diagnosis, n (%) | ||
| Favorable | 75 (6) | 67 (7) |
| Intermediate | 810 (64) | 634 (68) |
| Adverse | 334 (26) | 201 (21) |
| Missing | 47 (4) | 33 (4) |
| Remission status at HCT, n (%) | ||
| First remission | 1009 (80) | 760 (81) |
| Second remission | 257 (20) | 175 (19) |
| Pre-HCT MRD by flow cytometry, n (%) | 261 (21) | 136 (15) |
| Cytogenetics before HCT, n (%) | ||
| Normalized karyotype | 472 (37) | 361 (39) |
| Abnormal karyotype | 236 (19) | 134 (14) |
| Noninformative data∗ | 558 (44) | 440 (47) |
| Recovered peripheral blood counts before HCT,† n (%) | 891 (70) | 677 (72) |
| HCT-CI score, n (%) | ||
| 0-1 | 483 (38) | 367 (39) |
| 2-3 | 425 (34) | 314 (34) |
| ≥4 | 344 (27) | 246 (26) |
| Missing | 14 (1) | 8 (1) |
| HLA matching, n (%) | ||
| 10/10 HLA-identical related donor | 288 (23) | 214 (23) |
| 10/10 HLA-matched unrelated donor | 633 (50) | 471 (50) |
| 1-2 allele/antigen-mismatched unrelated donor | 137 (11) | 99 (11) |
| HLA-haploidentical donor | 51 (4) | 37 (4) |
| Umbilical cord blood | 157 (12) | 114 (12) |
| Source of stem cells, n (%) | ||
| Peripheral blood | 1022 (81) | 762 (81) |
| Bone marrow | 87 (7) | 59 (6) |
| Umbilical cord blood | 157 (12) | 114 (12) |
| Conditioning intensity, n (%) | ||
| MAC | 734 (58) | 569 (61) |
| Non-MAC | 532 (42) | 366 (39) |
| GVHD prophylaxis, n (%) | ||
| CNI + MMF w/wo sirolimus | 609 (48) | 418 (45) |
| CNI + MTX w/wo other | 457 (36) | 365 (39) |
| PTCy | 184 (15) | 139 (15) |
| Other | 16 (1) | 13 (1) |
| Post-HCT MRD status day +20 to +40, n (%) | ||
| MRDneg | 1123 (89) | 902 (96) |
| MRDpos | 99 (8) | 15 (2) |
| Not assessed | 44 (3) | 18 (2) |
| Post-HCT MRD status day +70 to +100, n (%) | ||
| MRDneg | 983 (78) | 924 (99) |
| MRDpos | 131 (10) | 11 (1) |
| Not assessed | 152 (12) | 0 (0) |
| Pre-HCT/day +70 to +100 post-HCT MRD dynamics, n (%) | ||
| MRDneg/MRDneg | 839 (66) | 798 (85) |
| MRDneg/MRDpos | 60 (5) | 1 (<1) |
| MRDpos/MRDneg | 144 (11) | 126 (13) |
| MRDpos/MRDpos | 71 (6) | 10 (1) |
| Not assessed | 152 (12) | 0 (0) |
| Day +20-40/day +70 to +100 post-HCT MRD dynamics, n (%) | ||
| MRDneg/MRDneg | 945 (75) | 897 (96) |
| MRDneg/MRDpos | 82 (6) | 5 (1) |
| MRDpos/MRDneg | 19 (2) | 9 (1) |
| MRDpos/MRDpos | 48 (4) | 6 (1) |
| Not assessed | 172 (14) | 18 (2) |
| CD3 chimerism day +70 to +100, n (%) | ||
| Mixed (<95%) | 307 (24) | 240 (26) |
| Full (≥95%) | 565 (45) | 474 (51) |
| Not assessed | 394 (31) | 221 (24) |
| Decreasing CD3 chimerism day +20 to +40 to day +70 to +100, n (%) | ||
| No (increase or <20% decrease) | 689 (54) | 564 (60) |
| Yes (≥20 decrease) | 14 (1) | 8 (1) |
| Not assessed | 563 (44) | 363 (36) |
ANC, absolute neutrophil count; CNI, calcineurin inhibitor; GVHD, graft-versus-host disease; MMF, mycophenolate mofetil; MTX, methotrexate; PTCy, posttransplantation cyclophosphamide; w/wo, with/without.
Normal cytogenetics in patient with cytogenetically normal disease or missing cytogenetics at diagnosis.
ANC ≥103/μL and platelets ≥105/μL.